ClinicalTrials.gg
CompletedNCT03105765Updated Apr 10, 2017

Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.

An interventional study of Placebo and Ketamine in Acute Pain, Chronic Pain and Neuropathic Pain, sponsored by Dr. Horst Schmidt Klinik GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-10.

Sponsored by Dr. Horst Schmidt Klinik GmbH · Not applicable, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing ketamine in Acute Pain — 1 open to participants now, 1 under way, none of them phase 3. Ketamine · Acute Pain.

Enrollment
4th of 38
200 · median 45
Started
2011
the only one that year
No phase
5 of 38
none open now
Registered
14th of 38
by date
Lead sponsor
1 of 38
Dr. Horst Schmidt Klinik GmbH

Among the 38 studies testing ketamine in Acute Pain, this one is the 4th largest by enrollment, is the only one that started in 2011, is one of 5 with no phase, and was the 14th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

1 of the 38 studies testing ketamine in Acute Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing ketamine in Acute Pain, or all of them as a file.
02

Study summary

Chronic Pain, especially neuropathic pain, are adverse events after posterolateral thoracotomy for lung resection. The continuous application of ketamine may have a prophylactic effect and helps to prevent chronic pain. The investigators record the incidence and severity of acute pain and neuropathic pain during a seven day period after thoracotomy as well as the incidence of chronic pain and neuropathic pain after one and three month period. Parallel Group design, comparing one Group with a continuous application (24 hours) of ketamine against a Placebo Group.

03

Conditions studied

  • Acute Pain
  • Chronic Pain
  • Neuropathic Pain

Keywords

  • Neuropathic Pain
  • Chronic Pain
  • Posterolateral thoracotomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • posterolateral thoracotomy for lung parenchyma resection
  • ASA () Status I-III

Exclusion criteria

Exclusion Criteria:

  • history of chronic pain
  • history of neuropathic pain
  • pregnancy or breastfeeding
  • participation in another trial
  • for ketamine
  • medication with can influence neuropathic pain (gabapentin, clonazepam)
  • history of neurological or behavioral illness
  • history of alcohol abuse
  • history of chemotherapy or radiation
  • opioid medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Ketamine

    The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium. Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours.

    Drug: Ketamine

  • Placebo comparator
    Placebo

    The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium. Placebo (normal Saline) for 24 hours.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.

  • Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.

06

What researchers measure

Primary outcomes

  1. Change in perioperative opioid consumption

    The patients consumption of opioids is recorded once a day for a period of 7 days after operation.

    Time frame: seven days after operation

  2. Change in acute pain

    The incidence and severity of pain will be measured using a numeric analog scale (NAS) once a day for a period of seven days after Operation.

    Time frame: 7 days after Operation

  3. acute neuropathic pain

    The incidence of neuropathic pain will be measured using the LANSS Pain Scale (Leeds assessment of neuropathic symptoms and signs) three and seven days after operation

    Time frame: 7 days after operation

Secondary outcomes

  1. Change in chronic Pain

    The incidence and severity of pain will be measured using a numeric analog scale (NAS). Pain scale is requested by phone one and three month after Operation.

    Time frame: one and three month after operation

  2. Chronic Neuropathic pain

    The incidence of neuropathic pain will be measured by using the LANSS Pain Scale (Leeds assessment of neuropathic symptoms and signs) one month after operation

    Time frame: one month after operation

  3. Chronic Neuropathic Pain

    The incidence of neuropathic pain will be measured by using the LANSS Pain Scale (Leeds assessment of neuropathic symptoms and signs) three month after operation

    Time frame: three month after operation

  4. recovery time

    Time between stopping intravenous anaesthesia and first eye opening of the Patient in minutes

    Time frame: eye opening after stopping anesthesia in minutes

07

Study locations

1 site
  • Dr. Horst Schmidt Klinik
    Wiesbaden, Hessen 65199, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Aug 2014 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2016
First posted
Apr 10, 2017
Start
Jan 2011
Primary completionActual
Aug 2014
CompletionActual
Aug 2016
Last update
Apr 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03105765
Lead sponsor
Dr. Horst Schmidt Klinik GmbH
Responsible party
Sponsor
First posted
Apr 10, 2017
Start date
Jan 2011
Primary completion
Aug 2014
Completion
Aug 2016
Last update
Apr 10, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion